Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.
J Dtsch Dermatol Ges
; 6(12): 1066-9, 2008 Dec.
Article
em En, De
| MEDLINE
| ID: mdl-19138272
ABSTRACT
Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers worldwide. Epidermal growth factor receptor (EGFR) is expressed at the cell surface by more than 90% of SCCs and its activation is responsible for cell cycle progression, proliferation, survival, angiogenesis and metastasis. Cyclooxygenase-2 (COX-2) is an enzyme up-regulated through EGFR signaling and responsible for some of the EGFR-dependent biological effects. An 88-year-old man presented with a recurrent, locoregionally meta-static SCC of the right parietal region, which was resistant to radiotherapy. With a combination therapy of an EGFR blocker (cetuximab) and a COX-2 inhibitor (celecoxib), the tumor regressed partially and the patient's Karnofsky index improved. We speculate that the combined use of cetuximab and COX-2 inhibitors can be a new and effective therapy for advanced and recurrent cutaneous SCCs.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirazóis
/
Neoplasias Cutâneas
/
Sulfonamidas
/
Carcinoma de Células Escamosas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Inibidores de Ciclo-Oxigenase 2
/
Receptores ErbB
/
Anticorpos Monoclonais
Tipo de estudo:
Diagnostic_studies
Limite:
Aged80
/
Humans
/
Male
Idioma:
De
/
En
Ano de publicação:
2008
Tipo de documento:
Article